Keck School of Medicine Researchers Discover PCBP1 Gene Target to Combat Fatal Infant Cardiomyopathy

USC researchers identify the PCBP1 gene as a potential treatment target for AARS2-related cardiomyopathy, a fatal infant heart disease with no current cure.

By: AXL Media

Published: Apr 21, 2026, 5:52 AM EDT

Source: Information for this report was sourced from the Keck School of Medicine of USC

Genetic Breakthrough Offers Alternative Path for Incurable Heart Disease

A significant advancement in pediatric cardiology has emerged as researchers shift their focus from direct mutation repair to secondary genetic intervention. For infants born with AARS2-related cardiomyopathy, the prognosis is historically grim, with the condition typically proving fatal within the first year of life. However, a new study led by the Keck School of Medicine of USC suggests that the PCBP1 gene acts as a vital controller for the heart’s cellular machinery. By manipulating this gene, scientists believe they can bypass the underlying AARS2 mutations that cause the heart muscle to fail, providing a novel therapeutic strategy for a previously untreatable disorder.

Mitochondrial Collapse Identified as Primary Driver of Heart Failure

The research team meticulously traced the molecular chain of events that leads to rapid cardiac decline in affected newborns. They discovered that when the PCBP1 protein is absent or dysfunctional, the genetic instructions for the AARS2 gene are processed incorrectly through a flawed splicing mechanism. This error directly cripples the mitochondria, which serve as the primary energy plants for heart cells. Without a steady supply of energy, the heart muscle cannot maintain its rhythmic contractions, triggering a cascade of stress signals that accelerate tissue damage and lead to total organ failure.

Innovative Mouse Models and Human Stem Cell Validation

To confirm these findings, investigators utilized a sophisticated genetic approach to delete the PCBP1 gene specifically within the heart muscle cells of mice. These animal models successfully reproduced the key clinical features of the human disease, allowing for a controlled study of the condition's progression. The team further validated these results using human induced pluripotent stem cells (iPSCs), which were programmed to become functioning heart cells in a laboratory setting. When PCBP1 was deactivated in these human cells, the same mitochondrial disruption occurred, proving that the biological mechanism is consistent across species.